SELLAS Life Sciences Group (SLS) News Today $0.93 +0.01 (+1.09%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period SELLAS Life Sciences Group, Inc.: SELLAS Announces Key Business Objectives for 2025January 8, 2025 | finanznachrichten.deSELLAS Announces Key Business Objectives for 2025January 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short InterestSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 7,460,000 shares, a decline of 17.6% from the November 30th total of 9,050,000 shares. Based on an average daily volume of 978,800 shares, the short-interest ratio is currently 7.6 days.December 29, 2024 | marketbeat.comPromising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences’ SLS009December 12, 2024 | markets.businessinsider.comSellas Life Sciences triggers interim analysis in Phase 3 REGAL trialDecember 10, 2024 | markets.businessinsider.comSellas Life Sciences reports OS, ORR data from Phase 2 trial of SLS009December 10, 2024 | markets.businessinsider.comSELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaDecember 10, 2024 | globenewswire.comSELLAS Stock Announces Positive Data From Phase 2 Trial Of SLS009December 9, 2024 | markets.businessinsider.comSELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AMLDecember 9, 2024 | globenewswire.com793,835 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Purchased by Anson Funds Management LPAnson Funds Management LP purchased a new position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 793,835 shares of the company's stock, valDecember 8, 2024 | marketbeat.comSellas Announces Positive Data From Preclinical Studies Of SLS009November 27, 2024 | markets.businessinsider.comSELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersNovember 27, 2024 | globenewswire.comPromising Clinical Trials and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences GroupNovember 16, 2024 | markets.businessinsider.comWe're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn RateNovember 16, 2024 | finance.yahoo.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | finanznachrichten.deSELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comSellas Life Sciences options imply 22.6% move in share price post-earningsNovember 12, 2024 | markets.businessinsider.comSELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024November 5, 2024 | globenewswire.comSELLAS' Galinpepimut-S Gets Rare Pediatric Disease Designation For Treatment Of Pediatric AMLOctober 15, 2024 | markets.businessinsider.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaOctober 15, 2024 | globenewswire.comMubadala’s Kelix bio acquires GHH’s pharma assets to expand its life sciences portfolioOctober 14, 2024 | msn.comSELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comSELLAS Life Sciences Gr (NASDAQ:SLS) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comSELLAS Life Sciences Gr (NASDAQ:SLS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBH Lynx SLS Mixes Softail & Full-Suspension Tech in Faster 80mm XC Race Mountain BikeSeptember 21, 2024 | yahoo.comSellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case TheorySeptember 18, 2024 | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 3.3%SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.3%September 7, 2024 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Drop in Short InterestSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 7,720,000 shares, a drop of 27.5% from the July 31st total of 10,650,000 shares. Based on an average daily volume of 919,800 shares, the days-to-cover ratio is currently 8.4 days.August 31, 2024 | marketbeat.comBuy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical TrialsAugust 15, 2024 | markets.businessinsider.comTriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comSELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings ResultsSELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03.August 15, 2024 | marketbeat.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deSLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024August 13, 2024 | markets.businessinsider.comSELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | globenewswire.comSELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 0.9%SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 0.9%August 7, 2024 | marketbeat.comSELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasAugust 6, 2024 | globenewswire.comSellas Life Sciences Group Share ChatAugust 5, 2024 | lse.co.ukSLS Aug 2024 0.500 callAugust 5, 2024 | ca.finance.yahoo.comSELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to MarketJuly 31, 2024 | finance.yahoo.comSELLAS Life Sciences announces $21M registered direct offeringJuly 31, 2024 | msn.comCitius Pharmaceuticals Inc (47N.BE)July 27, 2024 | finance.yahoo.comSLS Core Stage ArrivesJuly 25, 2024 | yahoo.comConnect Life Sciences Strengthens Board with Two New AppointmentsJuly 22, 2024 | msn.comStock Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders purchased 42,028 call options on the stock. This is an increase of 921% compared to the typical daily volume of 4,116 call options.July 16, 2024 | marketbeat.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaJuly 16, 2024 | globenewswire.comSELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJuly 8, 2024 | globenewswire.comSELLAS Life Sciences Group (NASDAQ:SLS) Upgraded at Royal Bank of CanadaRoyal Bank of Canada raised SELLAS Life Sciences Group to a "moderate buy" rating in a report on Monday.June 26, 2024 | marketbeat.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaJune 24, 2024 | globenewswire.comSELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaJune 17, 2024 | globenewswire.comStock Traders Purchase Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 5,244 call options on the company. This represents an increase of approximately 75% compared to the typical volume of 3,003 call options.June 12, 2024 | marketbeat.com Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Media Mentions By Week SLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼0.940.78▲Average Medical News Sentiment SLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼31▲SLS Articles Average Week Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies C4 Therapeutics News Candel Therapeutics News Benitec Biopharma News Foghorn Therapeutics News UroGen Pharma News Lifecore Biomedical News Heron Therapeutics News Atai Life Sciences News Eledon Pharmaceuticals News COMPASS Pathways News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLS) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
